The FDA has granted a priority review designation to a new drug application for capmatinib for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping—mutated non–small cell lung cancer.
Original Article: FDA Grants Priority Review to Capmatinib in METex14+ NSCLC